14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NBIX vs OKYO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NBIX carries a Unified Composite Score of 40.0/100 (SELL) at $150.57 (12.2x Forward P/E, 26.6% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While OKYO currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. NBIX 40.0/100 SELL), NBIX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+41.2% vs. +0.0% YoY).
Technical & Structure Timing Caution: NBIX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NBIX vs OKYO. Trailing 12-month operating profitability (NBIX 26.6% vs OKYO 0.0%) and valuation multiples (NBIX 12.2x vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NBIX vs OKYO Key Questions & Quantitative Answers
As of Nov 20, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NBIX carries a Unified Composite Score of 40.0/100 (SELL) at $150.57 (12.2x Forward P/E, 26.6% operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OKYO currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. NBIX 40.0/100 SELL), NBIX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+41.2% vs. +0.0% YoY). Technical & Structure Timing Caution: NBIX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NBIX leads the Growth & Scale pillar: NBIX posts +41.2% YoY revenue growth and -3.9% YoY earnings growth on $3.70B TTM revenue (64.7% gross margin, 26.6% operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NBIX generates $3.70B in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, NBIX deploys 38.1% of Rev ($1.41B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.
NBIX screens cheaper on headline valuation multiples. NBIX trades at 12.2x Forward P/E, 24.2x Trailing P/E, 0.32x PEG, and 4.2x EV/Revenue (28.1% FCF margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NBIX (20.4% ROE) versus OKYO (-263.8% ROE) capital efficiency.
In options market volatility and institutional positioning, NBIX carries 33.9% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.85x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 56% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.